As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Dogwood Therapeutics, Inc. The largest reported stake is Sealbond Limited's, at 75.2%. 5 filings are on record since November 25, 2025 (Schedule 13D/A, October 27, 2026).
Sell to companies like Dogwood Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Sealbond Limited · Sole voting: 25,920,693 · Shared voting: 0 · Sole dispositive: 25,920,693 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-10-27
- · Holder: Sealbond Limited · Percent: 72.3% · SCHEDULE 13D/A
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 3,384,798 · Sole dispositive: 0 · Shared dispositive: 3,384,798 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Armistice Capital, LLC · Percent: 9.99% · SCHEDULE 13G
- · Holder: Sealbond Limited · Percent: 83% · SCHEDULE 13D/A
Dogwood Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-11-25. 2 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Sealbond Limited | 75.2% | 25,920,693 | SCHEDULE 13D/A, 2026-10-27 | 2026-10-26 |
| Armistice Capital, LLC | 9.99% | 3,384,798 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Dogwood Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Dogwood Therapeutics, Inc. and the records around it.
Dogwood Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Dogwood Therapeutics, Inc.
Get an email when Dogwood Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Dogwood Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Dogwood Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dogwood Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Sealbond Limited | 25,920,693 | 0 | 25,920,693 | 0 | SCHEDULE 13D/A, 2026-10-27 |
| CK Life Sciences Int'l., (Holdings) Inc. | 28,763,331 | 0 | 28,763,331 | 0 | SCHEDULE 13D/A, 2026-10-27 |
| Conjoint Inc. | 2,842,638 | 0 | 2,842,638 | 0 | SCHEDULE 13D/A, 2026-10-27 |
| Armistice Capital, LLC | 0 | 3,384,798 | 0 | 3,384,798 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 3,384,798 | 0 | 3,384,798 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Dogwood Therapeutics, Inc. by CUSIP 92829J203 and gives its principal executive office as 44 Milton Avenue, Alpharetta, GA 30009 (SCHEDULE 13D/A, 2026-10-27).
Source of funds (Item 3)
Item 3 is hereby amended to add the following: On October 26, 2026 (the "Closing Date"), the transaction contemplated under the Subscription Agreement (as previously described in Item 4 of Amendment No. 3) was consummated. Pursuant to the terms of the Subscription Agreement, on the Closing Date, Sealbond Limited ("Sealbond") purchased from the Company 4,098,360 shares of Common Stock at a purchase price of $1.22 per share, for aggregate consideration of approximately $5,000,000 (the "Private Placement"). The shares were purchased using funds from working capital.Sealbond Limited, SCHEDULE 13D/A, 2026-10-27
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-25 | Sealbond Limited | 83% | SCHEDULE 13D/A |
| 2026-05-15 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-08-14 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-10-21 | Sealbond Limited | 72.3% | SCHEDULE 13D/A |
| 2026-10-27 | Sealbond Limited | 75.2% | SCHEDULE 13D/A |
Questions about who owns Dogwood Therapeutics, Inc.
Who owns Dogwood Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Dogwood Therapeutics, Inc.: Sealbond Limited (75.2%, Schedule 13D/A, filed 2026-10-27) and Armistice Capital, LLC (9.99%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Dogwood Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Dogwood Therapeutics, Inc. on this page are Sealbond Limited (75.2%) and Armistice Capital, LLC (9.99%).
When did Sealbond Limited buy into Dogwood Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Sealbond Limited on this page is the Schedule 13D/A, filed 2025-11-25, reporting 83%; its latest, Schedule 13D/A filed 2026-10-27, reports 75.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Dogwood Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.